These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23128975)

  • 21. Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection.
    Schmidt RH; Lenz T; Gröne HJ; Geiger H; Scheuermann EH
    Nephrol Dial Transplant; 1999 Apr; 14(4):979-83. PubMed ID: 10328486
    [No Abstract]   [Full Text] [Related]  

  • 22. [Case of encephalopathy seemingly caused by tacrolimus at blood concentration near the upper limit of therapeutic range].
    Yamaguchi K; Fukuoka N; Kimura S; Shinohara N; Tatsumichi T; Tai T; Kosaka S; Ohnishi H; Houchi H
    Yakugaku Zasshi; 2012; 132(7):845-8. PubMed ID: 22790031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease.
    Olson KA; West K; McCarthy PL
    Pharmacotherapy; 2014 Jun; 34(6):e60-4. PubMed ID: 24700567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient.
    Cox TH; Baillie GM; Baliga P
    Pharmacotherapy; 1997; 17(6):1328-30. PubMed ID: 9399620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxic Tacrolimus Concentrations Associated With Intravenous Use of Metoclopramide in a Lung Transplant Patient.
    Provenzani A; D'alessandro N; Polidori P
    Ann Pharmacother; 2019 May; 53(5):548-549. PubMed ID: 30739475
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of high-risk chronic GVHD.
    Pavletic S; Vogelsand GB
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1436-7. PubMed ID: 19041069
    [No Abstract]   [Full Text] [Related]  

  • 27. Decreasing pancreatic toxicity of tacrolimus by dosage reduction.
    Uchida K; Tominaga Y; Haba T; Katayama A; Ichimori T; Yamada K; Hibi Y; Uemura O; Morozumi K; Takagi H
    Transplant Proc; 1998 Jun; 30(4):1276-8. PubMed ID: 9636518
    [No Abstract]   [Full Text] [Related]  

  • 28. Anaphylaxis Induced by Intravenous Tacrolimus Administration During Kidney Transplant Surgery: A Case Report.
    Yamamoto R; Saito M; Abe K; Saito T; Sagehashi R; Nara T; Numakura K; Narita S; Satoh S; Habuchi T
    Transplant Proc; 2021 May; 53(4):1292-1294. PubMed ID: 33714607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tacrolimus in adult hematopoietic stem cell transplantation.
    Gao Y; Ma J
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):803-811. PubMed ID: 31595800
    [No Abstract]   [Full Text] [Related]  

  • 30. Topical tacrolimus in the management of oral lichen planus: literature review.
    Shilpa PS; Kaul R; Bhat S; Sanjay CJ; Sultana N
    J Calif Dent Assoc; 2014 Mar; 42(3):165-70. PubMed ID: 25080722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublingual administration of tacrolimus in a renal transplant patient.
    Romero I; Jiménez C; Gil F; Escuin F; Ramirez E; Fudio S; Borobia A; Carcas A
    J Clin Pharm Ther; 2008 Feb; 33(1):87-9. PubMed ID: 18211623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of sublingual tacrolimus in lung transplant recipients.
    Watkins KD; Boettger RF; Hanger KM; Leard LE; Golden JA; Hoopes CW; Singer JP
    J Heart Lung Transplant; 2012 Feb; 31(2):127-32. PubMed ID: 22177691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.
    Przepiorka D; Ippoliti C; Khouri I; Woo M; Mehra R; Le Bherz D; Giralt S; Gajewski J; Fischer H; Fritsche H; Deisseroth AB; Cleary K; Champlin R; Besien K; Andersson B; Maher R; Fitzsimmons W
    Blood; 1996 Dec; 88(11):4383-9. PubMed ID: 8943876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus induced dermatophyte infection overlying a plaque morphea.
    Bhari N; Saginatham H; Verma KK
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27502443
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical features of calcineurin inhibitor-induced pain syndrome after allo-SCT.
    Kakihana K; Ohashi K; Murata Y; Tsubokura M; Kobayashi T; Yamashita T; Sakamaki H; Akiyama H
    Bone Marrow Transplant; 2012 Apr; 47(4):593-5. PubMed ID: 21625227
    [No Abstract]   [Full Text] [Related]  

  • 36. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
    Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L
    Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691
    [No Abstract]   [Full Text] [Related]  

  • 38. Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation.
    Ichikawa Y; Hanafusa T; Kyo M; Fukunishi T; Nagano S
    Int J Urol; 1996 May; 3(3):180-3. PubMed ID: 8776613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation.
    Mimura A; Yamaori S; Ikemura N; Katsuyama Y; Matsuzawa N; Ohmori S
    J Clin Pharm Ther; 2019 Aug; 44(4):565-571. PubMed ID: 30950099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
    Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
    J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.